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Objectives The aim of this study was to investigate the impact of cardiac resynchronization therapy (CRT) on right ventricu-
lar (RV) function and the influence of RV dysfunction on the echocardiographic and clinical response to CRT
among patients enrolled in the CARE-HF (Cardiac Resynchronization-Heart Failure) trial.
Background Cardiac resynchronization therapy prolongs survival in appropriately selected patients with heart failure but the
benefit might be diminished in patients with RV dysfunction.
Methods Of 813 patients enrolled in the CARE-HF study, 688 had tricuspid plane systolic excursion (TAPSE) measured at
baseline, and 345 of these were assigned to CRT. Their median (interquartile range) age was 66 (58 to 71)
years, left ventricular (LV) ejection fraction was 24% (21% to 28%), and TAPSE was 19 (16 to 22) mm. Baseline
LV function and size and QRS duration were similar among TAPSE tertiles, but those in the worst tertile (TAPSE
17.4 mm) were more likely to have ischemic heart disease.
Results Overall, CRT improved LV but not RV structure and function with little evidence of an interaction with TAPSE.
During a median (interquartile range) follow-up of 748 (582 to 950) days, 213 deaths occurred. Patients with
lower TAPSE had a higher mortality, regardless of assigned treatment (p  0.001). Greater inter-ventricular me-
chanical delay, New York Heart Association functional class, mitral regurgitation, and N-terminal pro–B-type na-
triuretic peptide, lower TAPSE, and assignment to the control group were independently associated with higher
mortality. Reduction in mortality with CRT was similar in each tertile of TAPSE.
Conclusions Right ventricular dysfunction is a powerful determinant of prognosis among candidates for CRT, regardless of
treatment assigned, but did not diminish the prognostic benefits of CRT among patients enrolled in the CARE-HF
trial. (Care-HF CArdiac Resynchronization in Heart Failure; NCT00170300) (J Am Coll Cardiol 2013;61:
2153–60) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.049Right ventricular (RV) dysfunction indicates a poor prog-
nosis in patients with heart failure (1,2). Cardiac resynchro-
nization therapy (CRT) improves left ventricular (LV)
function, symptoms, and prognosis in patients with symp-
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longed QRS duration (3). However, uncertainty exists both
about the effects of CRT on RV function (4–9) and how
RV dysfunction affects the response to CRT (4–10). How-
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Right Ventricular Function in CARE-HF May 28, 2013:2153–60ever, observational studies mea-
sure outcome with but not the
response to an intervention. A
control group is required to dis-
tinguish treatment effects from
the natural history of the disease
(11). A post-hoc analysis of the
REVERSE (REsyncronization re-
VErses Remodeling in Systolic left
vEntricular dysfunction) trial, in-
cluding 450 patients with chronic
heart failure and mild symptoms,
suggested that those with RV
dysfunction (tricuspid annular plane
systolic excursion [TAPSE] 14
mm) had a diminished response
to CRT (n  61), with less
reverse LV remodelling and a poorer symptomatic
response (12).
We investigated the impact of CRT on RV function and
the influence of RV dysfunction on the echocardiographic
and clinical response to CRT among patients enrolled in
the CARE-HF (Cardiac ResynchronizationHeart Fail-
ure) trial (13).
Methods
The CARE-HF trial was a randomized trial of 813 patients
(3) who had symptoms of heart failure despite guideline-
indicated treatment who were in sinus rhythm and had LV
systolic dysfunction and dilation and markers of cardiac
dyssynchrony.
This analysis is based on 688 patients (85% of all patients
in the CARE-HF trial) who had a measurement of lateral
wall TAPSE at baseline by M-mode (13). In addition to
TAPSE, echocardiographic measurements included: LV
end-diastolic and end-systolic volumes, left ventricular ejec-
tion fraction (LVEF), RV end-diastolic area and end-
systolic area, RV fractional shortening area, mitral regurgi-
tation and tricuspid regurgitation (TR) by measuring the
area of the jet divided by the area of the right atrium on
color flow Doppler and trans-tricuspid gradient pressure.
Echocardiography was repeated at 3, 9, and 18 months.
Statistical methods. Continuous data were summarized by
the median (25th/75th) percentiles; categorical data were
summarized by percentages. An analysis of variance model
was used to look at the trend for continuous variables; the
chi-squared test was used to look for trend for categorical
variables (Tables 1 and 2). Data are shown by tertile of
TAPSE. The primary outcome measure of the CARE-HF
trial was all-cause mortality or an unplanned hospital stay
for a major cardiovascular event. All-cause mortality was the
principal secondary endpoint and the primary endpoint of
an extension phase (3).
Survival curves were constructed with the Kaplan-Meier
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
IHD  ischemic heart
disease
LV  left ventricle
LVEF  left ventricular
ejection fraction
MR  mitral regurgitation
RV  right ventricle
TAPSE  tricuspid annular
plane systolic excursion
TR  tricuspid
regurgitationmethod; univariate and multivariate Cox regression model-ing were performed to assess the independent impact of
TAPSE on clinical outcome (14,15). We explored whether
the inclusion of 3 additional covariates—TAPSE, TR
jet/right atrial diastolic area, and TR pressure gradient—
added prognostic value to previous models (14,15). Both
baseline and 3-month post-implant values were considered.
Where the proportional hazards assumption was violated,
Cox models with time-dependent effects were considered.
Over-fitting and goodness-of-fit was also addressed. Miss-
ing values at 3 months were imputed from baseline values to
preserve the integrity of randomization.
Results
The maximum and minimum values for TAPSE in each
tertile were 5.5 to 17.3 mm, 17.4 to 21.1 mm, and 21.2 to
33.4 mm, respectively; 93 patients had values 14 mm.
Patients in the lowest tertile of TAPSE were more often
men, were twice as likely to have ischemic heart disease
(IHD), and had evidence of more severe heart failure (Table 1).
Cardiac resynchronization therapy reduced LV end-
systolic and -diastolic volumes and increased LVEF within
3 months of implantation, with evidence of further benefit
by 9 months, which was sustained at 18 months (16). Mitral
regurgitation was reduced by 3 months, and the effect was
sustained (Table 2). Overall, CRT did not improve RV
structure and function. The effects of CRT on LV structure
and function and mitral regurgitation and the lack of effect
on RV structure and function were broadly similar across
tertiles of TAPSE, although patients in the worst tertile had
a slightly greater reduction in RVES area and TR gradient
(Table 2). Results for RV structure and function were
similar when patients were divided according to the pres-
ence or absence of IHD (Fig. 1).
Among patients with a TAPSE measurement, 329 reached
the primary endpoint (T1 145, T2 99, T3 85), and 213
ied (Fig. 2). The median (interquartile range) follow-up,
ensored for death, was 748 days (58 to 950) days. A higher
APSE at baseline was associated with a lower risk of the
rimary outcome (chi-square log-rank test: 27.1; p 0.001)
nd better survival (chi-square log-rank test: 12.4; p 
.001), regardless of treatment assigned. However, the effect
f CRT on outcome was similar across tertiles of TAPSE
Figs. 2A and 2B). Analysis confined to the 93 patients with
TAPSE 14 mm also showed similar improvement in
utcome, both for the primary endpoint (hazard ratio: 0.57,
5% confidence interval: 0.34 to 0.94, p  0.029) and
all-cause mortality (hazard ratio: 0.62, 95% confidence
interval: 0.34 to 1.11, p  0.11). Patients with worse
TAPSE were more likely to die of heart failure. Caution
should be applied to interpretation of CRT effects on mode
of death in subgroups, due to the small number of events
(Fig. 2B).
Adding measures of RV function to a published multi-
variable model (14) eliminated IHD as a predictor of
mortality, replacing it with TAPSE measured at 3 months
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May 28, 2013:2153–60 Right Ventricular Function in CARE-HFafter randomization (Table 3). The following variables, as in
the original published model, remained independently associ-
ated with higher all-cause mortality: less interventricular me-
chanical delay at baseline; New York Heart Association
functional class IV at baseline; assignment to the control
group; more severe mitral regurgitation at 3 months; and
higher N-terminal pro–B-type natriuretic peptide at 3
months (14) (Table 3). The model did not suffer from
over-fitting (17). The proportional hazards assumption was
not violated (overall chi-square test 4.2, df 6, p 0.64)
18). In univariate analyses, LV volumes and LVEF mea-
Clinical, Biological, and Echocardiography CharaEntire Population and Divided by Tertiles of TAPTable 1 Clinic l, Biological, and EchocardioEntire Population and Divided by Te
Baseline Characteristics
T1
(n  233)
Clinical
Age, yrs 66 (60–73)
Men 195 (84)
NYHA functional class IV 15 (6)
BMI (kg/m2) 25 (23–28)
Heart rate, beats/min 71 (62–83)
Systolic BP, mm Hg 110 (100–120)
LBBB 206 (88)
QRS duration (ms) 160 (150–180)
Ischemic heart disease 121 (52)
NT-proBNP (pg/ml) 3,023 (1,310–5,97
eGFR, ml/min/1.73 m2 53 (42–67)
Echocardiography
LVEDV (ml) 296 (246–354)
LVESV (ml) 225 (180–273)
LVEF (%) 23 (20–26)
LA diastolic area 23 (18–29)
MR jet area (mm2) 25 (15–35)
IVMD, ms 46 (26–64)
RVED area, cm2 23 (18–29)
RVES area, cm2 16 (10–20)
RV fractional shortening area, % 31 (23–40)
TAPSE, mm 14 (12–16)
TR jet area, cm2 3.4 (1.8–6.4)
TR jet available 179 (77)
RA diastolic area, cm2 16.2 (10.8–21.4)
TR jet area/RA area cm2 21.9 (15.2–33.6)
TR gradient, mm Hg 33 (24–42)
TR gradient available 141 (60)
Treatment
Beta-blockers 164 (70)
ACE inhibitors/ARB 220 (94)
Aldosterone inhibitor 131 (56)
Furosemide 80 mg/day 134 (57)
Digitalis 91 (39)
Values are median (25th/75th percentiles) or n (%).
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensi
estimated glomerular filtration rate; IVMD  interventricular mechan
ventricular end-diastolic volume; LVESV  left ventricular end-systol
natriuretic peptide; NYHA New York Heart Association; RA right at
right ventricular end-systolic area; TAPSE  tricuspid annular plane syured at 3 months were more strongly related to prognosis than measurements at baseline, but none contributed inde-
endent prognostic information on a multivariable analysis.
iscussion
his analysis shows that CRT has little effect on RV
unction and that the severity of RV dysfunction is a weak
eterminant of the effects of CRT on LV structure or
unction. Although a marker of a worse overall prognosis,
V dysfunction was not an important determinant of the
elative benefits of CRT.
As far as we are aware, this is the first study to investigate
istics at Baseline iny Characteristics at Baseline in
of TAPSE
TAPSE Tertiles (n  688)
T2
(n  231)
T3
(n  224)
p Value
for Trend
58 (51–66) 65 (57–71) 0.07
150 (65) 155 (69) 0.001
16 (7) 11 (5) 0.5
26 (23–29) 27 (24–30) 0.001
68 (60–77) 69 (60–76) 0.01
117 (105–130) 120 (110–130) 0.001
207 (89) 206 (91) 0.05
165 (154–180) 160 (152–180) 0.87
65 (28) 44 (20) 0.001
1,792 (727–4,287) 1,099 (566–2,740) 0.001
59 (43–72) 64 (49–77) 0.001
307 (237–384) 295 (235–385) 0.82
222 (168–294) 219 (167–290) 0.001
24 (21–29) 25 (22–29) 0.001
19 (14–23) 18 (15–24) 0.001
23 (13–32) 16 (9–30) 0.001
48 (33–65) 51 (31–72) 0.034
20 (16–24) 19 (16–22) 0.001
11 (8–14) 10 (7–13) 0.001
43 (36–50) 47 (38–54) 0.001
19 (18–20) 23 (22–25) 0.001
2.2 (1.3–4.0) 1.8 (1–3) 0.001
160 (69) 137 (61) 0.001
11 (8.9–14.7) 10.5 (8.8–13) 0.001
18.9 (12.5–29.6) 15.3 (10.4–25.9) 0.001
28 (21–36) 28 (21–37) 0.011
124 (53) 79 (37) 0.001
164 (70) 172 (77) 0 .12
219 (94) 212 (94) 0.91
129 (55) 125 (55) 0.92
89 (38) 68 (30) 0.001
96 (41) 109 (48) 0.039
tor blocker; BMI  body mass index; BP  blood pressure; eGFR 
lay; LA  left atrial; LBBB  left bundle branch block; LVEDV  left
e; MR  mitral regurgitation; NT-proBNP  N-terminal pro–B-type
 right ventricle; RVED right ventricular end-diastolic area; RVES
xcursion; TR  tricuspid regurgitation.cterSEgraph
rtiles
9)
n recep
ical de
ic volumhe effect of CRT on RV function in a randomized
Changes in Quality of Life and Cardiac Function Between Baseline and 9 MonthsTable 2 Changes in Quality of Life and Cardiac Function Between Baseline and 9 Months
TAPSE Tertiles
T1 T2 T3 p Value
CRT Medical CRT Medical CRT Medical
Control vs.
CRT
Interaction
TAPSE vs. CRT
Number with paired results 89 75 94 92 85 93
LVEDV (ml) 27 (67 to3) 1 (29 to 15) 59 (98 to22) 11 (39 to 7) 49 (107 to6) 6 (38 to 16) 0.001 0.11
LVESV (ml) 30 (66 to10) 7 (30 to 11) 60 (95 to19) 11 (32 to 7) 46 (96 to12) 9 (37 to 9) 0.001 0.15
LVEF (%) 4 (1.3 to 9.2) 0.9 (0.9 to 3.2) 5.6 (1.1 to 10.8) 1 (1.7 to 3.7) 6.2(1.6 to 11.9) 1.2 (0.7 to 4.2) 0.001 0.12
LA diastolic area, cm2 4.8 (8.4 to 1.8) 3.7 (7.1 to 2.2) 3.8 (7.7 to 0.6) 1.9 (7.0 to 1.7) 5.2 (9.2.07) 2.4 (3.7 to 0.8) 0.01 0.24
MR jet area (%) 4 (13 to2) 0 (11 to 9) 4 (14 to 1) 0 (9 to 5) 3 (9 to 3) 2 (3 to 10) 0.001 0.22
IVMD (ms) 24 (41 to4) 0 (17 to 15) 21 (38 to9) 5 (21 to 10) 24 (40 to2) 1 (9 to 13) 0.001 0.13
TAPSE (mm) 1.1 (0.1 to 3.7) 1.4 (0.7 to 4.1) 0.4 (.1 to 3.6) 0.8 (1.1 to 2.8) 1.0 (3.5 to 0.1) .2.1 (3.6 to 0.8) 0.50 0.79
RVED area (cm2) 1 (7.4 to 1.1) 0.1 (3.1 to 2.5) 0.9 (3.7 to 1.4) 1.6 (3.4 to 0.7) 1.2 (3.5 to 0.7) 0.9 (3.5 to 2.0) 0.34 0.10
RVES area (cm2) 2.9 (6.4 to 0.7) 1.0 (4.4 to 1.9) 0.4 (4 to 0.5) 1.0 (2.8 to 0.7) 0.8 (2.5 to 1.7) 1.0 (2.8 to 0.3) 0.38 0.03
RV fractional shortening area (%) 6 (1 to 15) 5 (0 to 13) 4 (4 to 11) 3 (3 to 8) 1 (11 to 5) 3 (3 to 13) 0.38 0.36
Paired TR jet 41 (46%) 60 (80%) 45 (48%) 46 (50%) 47 (55%) 61 (66%)
TR jet area (cm2) 0.6 (2.3 to 0.8) 0.5 (2.2 to 0.9) 0.4 (1.3 to 1.4) 0.4 (1.7 to 0.3) 0.1 (1.2 to 1.1) 0.1 (1 to 0.5) 0.41 0.78
RA diastolic area (cm2) 0.9 (7.7 to 1.4) 1.3 (4.3 to 0.9) 0.9 (3.9 to 1.9) 0.6 (4.7 to 1.2) 0.5 (2.5 to 1.4) 1.1 (3.8 to 1) 0.56 0.39
TR jet area/RA area (cm2) 4.5 (14.9 to 5.6) 1.3 (11.5 to 9.1) 2.2 (9.2 to 11.7) 0.8 (14.3 to 4.8) 3.8 (4.2 to 12) 2.8 (13.4 to 10.8) 0.32 0.20
Paired TR gradient 29 (33%) 28 (37%) 32 (34%) 16 (17%) 22 (26%) 20 (22%)
TR gradient, mm Hg 8 (11.7 to3.4) 1.6 (10.5 to 6.3) 0.4 (5.6 to 3.7) 2.8 (6.1 to 2.8) 0 (9.2 to 2.7) 5.1 (7.5 to1.5) 0.42 0.03
p for interaction between CRT and TAPSE level from an analysis of variance model combining TAPSE levels 2/3.
CRT  cardiac resynchronization therapy; other abbreviations as in Table 1.
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May 28, 2013:2153–60 Right Ventricular Function in CARE-HFcontrolled trial. Cardiac resynchronization therapy might be
expected to improve RV function by lowering left atrial and
pulmonary artery pressures due to improvements in LV
function and mitral regurgitation (19 –22). However,
pacing leads might interfere with tricuspid valve function
and RV apical pacing might impair RV function (23).
However, we identified no substantial improvement in
right heart function with CRT when compared with
pharmacological therapy alone, in contrast to several
(7,19), but not all (24), observational studies, although
we might have missed subtle changes that can be mea-
sured by newer echocardiographic techniques, such as
tissue Doppler or RV strain (24,25).
At baseline, LV systolic dysfunction was similar across
tertiles of TAPSE, but those with worse TAPSE had more
severe mitral regurgitation, higher pulmonary artery pres-
sure, more severe TR and higher plasma concentration of
Figure 1 Effects of CRT
Effects (between baseline and 9 months) of cardiac resynchronization therapy (CR
(A), tricuspid regurgitation gradient (TRG) (B), right ventricular end-diastolic area (
stolic volume (LVEDV) (E), and left ventricular end-systolic volume (LVESV) (F) in p
the presence or absence of ischemic heart disease (IHD).N-terminal pro–B-type natriuretic peptide. The extent towhich RV dysfunction reflects pulmonary hypertension or
intrinsic RV dysfunction is uncertain and likely to vary over
time and among individual patients (26). However, the high
prevalence of IHD in patients with worse TAPSE suggests
that RV ischemic damage might be common (7,19 –22,
24–26). Poor baseline RV function was associated with a
trend to smaller improvements in LV function in response
to CRT, consistent with a previous report (12). However,
this trend was accounted for by the high prevalence of IHD
in patients with RV dysfunction. Patients with IHD are
more likely to have myocardial scar, which will impair the
beneficial remodeling response to both pharmacological
interventions and CRT (27,28).
There is growing evidence, reinforced by this analysis,
that RV rather than LV dysfunction might be the more
important determinant of prognosis (1,26). Both lower
TAPSE and higher TR gradient estimated at baseline were
pared with a control group on tricuspid annular plane systolic excursion (TAPSE)
(C), right ventricular (RV) fractional shortening area (D), left ventricular end-dia-
s in the lowest compared with the 2 highest tertiles (T) of TAPSE according toT) com
RVED)
atientassociated with an adverse prognosis, and this relationship
2158 Damy et al. JACC Vol. 61, No. 21, 2013
Right Ventricular Function in CARE-HF May 28, 2013:2153–60was strengthened when re-estimated at 3 months after
randomization. Interestingly, after measures of RV dys-
function were added to the prognostic model, the pres-
ence of IHD was no longer an independent predictor of
outcome. This could also reflect the importance of RV
damage due to ischemia (29). Whether, RV dysfunction
or etiology is the more important driver of an adverse
Figure 2 Mortality and Unplanned Hospitalization in Lowest Ve
TAPSE and Mode of Death Comparison Between Terti
(A) Death or unplanned hospital stay for a major cardiovascular event (MACE) in l
or to CRT (solid line) (chi-square log-rank test: 40.1; p  0.001). Unadjusted haza
stay in the main study: Tertile 1: 0.61 (95% confidence interval [CI]: 0.44 to 0.85
CI: 0.34 to 0.83), p  0.006. (B) Mortality in lowest versus 2 highest tertiles of T
log-rank test: 56.6; p  0.001). Unadjusted hazard ratio for patients assigned to
0.91), p  0.017; Tertile 2: 0.82 (95% CI: 0.49 to 1.34), p  0.45; Tertile 3: 0.3
heart failure; other abbreviations as in Figure 1.prognosis is uncertain. The strong statistical associationbetween worse TAPSE and higher prevalence of IHD
suggests that one might just be a surrogate for the other
in such models.
Several observational (6,10) studies have suggested that
patients with RV dysfunction receive less prognostic benefit
from CRT. The problem with observational studies is that
they are unable to distinguish between outcome with
2 Highest Tertiles of
versus 2 highest tertiles of TAPSE in patients assigned to control (dotted line)
ios for patients assigned to CRT versus control for death or unplanned hospital
0.004; Tertile 2: 0.59 (95% CI: 0.40 to 0.89), p  0.012; Tertile 3: 0.53 (95%
in patients assigned to control (dotted line) or to CRT (solid line) (chi-square
rsus control for death in extension phase study: Tertile 1: 0.61 (95% CI: 0.41 to
% CI: 0.20 to 0.68), p  0.002. SCD  sudden cardiac death; WHF  worseningrsus
le
owest
rd rat
), p 
APSE
CRT ve
7 (95treatment and response to it (11). This analysis confirms
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May 28, 2013:2153–60 Right Ventricular Function in CARE-HFprevious reports showing that, in patients who receive
CRT, those with poor RV function will have a worse
outcome. However, the change in prognosis (i.e., the
response to treatment) is similar in patients with and
without RV dysfunction. This contradicts assertions that
CRT is ineffective in patients with substantial RV dys-
function (6,10). Whether the severity of RV dysfunction
should influence the choice between CRT and CRT with
defibrillator is uncertain. Patients with RV dysfunction
are more likely to die of heart failure rather than
suddenly. However, sudden death still represents a sub-
stantial proportion of deaths in patients with RV dys-
function, which might be reduced by implantation of
CRT with defibrillator.
Study limitations. The current hypothesis was not defined
prior to conducting the study. Ideally, the results should be
confirmed in a prospective trial of patients with both RV
and LV dysfunction, but it is not clear whether this would
receive ethical clearance. Alternatively, data might be avail-
able from another randomized trial that could be analyzed,
retrospectively. A study of the size and duration of the
CARE-HF trial is unlikely to have missed substantial effects
of CRT on RV function but more modern imaging tech-
nologies might identify subtler effects. On the other hand,
the study was not adequately powered to investigate the
effects of CRT on outcomes, such as mode of death in
subgroups of patients.
Conclusions
Right ventricular dysfunction is a powerful determinant
of prognosis among candidates for CRT, regardless of
treatment assigned, but does not diminish the prognostic
benefits of CRT among patients enrolled in the CARE-HF
trial.
These data illustrate the difference between “outcome with”
and “response to” CRT, urging caution in the interpretation of
observational data, and might help clinicians make appropriate
Multivariable Cox Regression Models With Baselineand 3-Month Data to Predict All-Cau e MortalityTable 3 Mul ivariable Cox Regression Mod ls With Baselineand 3-Month Data to Predict All-Cause Mortality
Variables HR (95% CI) p Value
NYHA functional class IV 2.16 (1.28–3.63) 0.004
NT-proBNP, 3 months (pg/ml)* 1.62 (1.41–1.86) 0.001
MR, 3 months (cm2)* 1.01 (1.00–1.02) 0.001
IVMD (ms) 0.98 (0.98–0.99) 0.001
CRT 0.57 (0.53–0.99) 0.04
TAPSE, 3 months (mm)* 0.58 (0.40–0.84) 0.004
TAPSE (mm)* by tertile
T2 0.76 (0.56–1.04) 0.09
T3 0.69 (0.50–0.97) 0.03
Missing 0.97 (0.59–1.58) 0.91
NT-proBNP transformed by natural logarithms. *3-month values imputed by last observation
carried forward where baseline data missing. The TAPSE by tertile replaced TAPSE continuous
(mm), adjusting for same covariates. Hazard ratio (HR) for missing TAPSE gives an indication of
bias.
Q  quartile; other abbreviations as in Table 1.clinical choices for their patients.Reprint requests and correspondence: Dr. Thibaud Damy, Fé-
dération de Cardiologie at the AP-HP, Groupe Henri-Mondor
Albert-Chenevier, Créteil F-94010, France. E-mail: thibaud.damy@
hmn.aphp.fr.
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